Scholar Rock price target raised to $58 from $44 at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado raised the firm’s price target on Scholar Rock (SRRK) to $58 from $44 and keeps a Buy rating on the shares. The firm has increased confidence in apitegromab’s launch trajectory following key opinion leader feedback. Physicians consistently highlighted that additional FDA interactions and greater clarity around manufacturing remediation have reduced uncertainty, with several noting that Scholar Rock’s parallel supply chain strategy meaningfully de-risks early launch execution, the analyst tells investors in a research note.